2009
Dipeptidyl Peptidase-IV Inhibitor Use Associated With Increased Risk of ACE Inhibitor-Associated Angioedema
Brown NJ, Byiers S, Carr D, Maldonado M, Warner BA. Dipeptidyl Peptidase-IV Inhibitor Use Associated With Increased Risk of ACE Inhibitor-Associated Angioedema. Hypertension 2009, 54: 516-523. PMID: 19581505, PMCID: PMC2758288, DOI: 10.1161/hypertensionaha.109.134197.Peer-Reviewed Original ResearchConceptsACE inhibitorsRisk of angioedemaVildagliptin useDPP-IV inhibitorsComparator-treated patientsEnzyme (ACE) inhibitor-associated angioedemaStudy drug exposureAngiotensin receptor blockersPhase III studyPossible drug-drug interactionsIncidence of angioedemaCase report formsDipeptidyl peptidase IV inhibitorsDrug-drug interactionsDPP-IV inhibitor vildagliptinPathogenesis of angiotensinPeptidase IV inhibitorsAngioedema riskClinical angioedemaReceptor blockersIII studyAbsolute riskAdjudication committeeDPP-IV inhibitionDrug exposure
1997
Recurrent Angiotensin-Converting Enzyme Inhibitor—Associated Angioedema
Brown N, Snowden M, Griffin M. Recurrent Angiotensin-Converting Enzyme Inhibitor—Associated Angioedema. JAMA 1997, 278: 232-233. DOI: 10.1001/jama.1997.03550030072037.Peer-Reviewed Original ResearchConceptsACE inhibitor useAngiotensin converting enzyme (ACE) inhibitorsACE inhibitorsInhibitor useRecurrent angioedemaEnzyme inhibitorsEpisodes of angioedemaRate of angioedemaRetrospective cohort studyDiagnosis of angioedemaRisk of angioedemaTennessee Medicaid programAngioedema recurrencesCohort studySerious morbidityRecurrent episodesMedical recordsAssociated angioedemaMultiple recurrencesMedicaid enrolleesAngioedemaPatientsRecurrenceNumber of causesMedicaid programRecurrent angiotensin-converting enzyme inhibitor--associated angioedema.
Brown N, Snowden M, Griffin M. Recurrent angiotensin-converting enzyme inhibitor--associated angioedema. JAMA 1997, 278: 232-3. PMID: 9218671, DOI: 10.1001/jama.278.3.232.Peer-Reviewed Original ResearchConceptsACE inhibitor useACE inhibitorsInhibitor useRecurrent angioedemaEnzyme inhibitorsAngiotensin-converting enzyme inhibitorEpisodes of angioedemaRate of angioedemaRetrospective cohort studyDiagnosis of angioedemaRisk of angioedemaTennessee Medicaid programAngioedema recurrencesCohort studySerious morbidityRecurrent episodesMedical recordsAssociated angioedemaMultiple recurrencesMedicaid enrolleesAngioedemaPatientsRecurrenceNumber of causesMedicaid program
1996
Black Americans have an increased rate of angiotensin converting enzyme inhibitor‐associated angioedema
Brown N, Ray W, Snowden M, Griffin M. Black Americans have an increased rate of angiotensin converting enzyme inhibitor‐associated angioedema. Clinical Pharmacology & Therapeutics 1996, 60: 8-13. PMID: 8689816, DOI: 10.1016/s0009-9236(96)90161-7.Peer-Reviewed Original ResearchConceptsACE inhibitor useEnzyme (ACE) inhibitor-associated angioedemaInhibitor useACE inhibitorsRelative riskWhite subjectsACE inhibitor-associated angioedemaACE inhibitor doseRate of angiotensinRetrospective cohort studyRisk of angioedemaTennessee Medicaid programAssociation of racePotential confounding factorsEffect of doseSpecific ACE inhibitorDiuretic useCohort studyConcurrent medicationsPatient characteristicsPrevious hospitalizationAngioedemaInhibitor doseConfounding factorsYears of useAngiotensin converting enzyme inhibitor‐associated angioedema: higher risk in blacks than whites
Burkhart G, Brown N, Griffin M, Ray W, Hammerstrom T, Weiss S. Angiotensin converting enzyme inhibitor‐associated angioedema: higher risk in blacks than whites. Pharmacoepidemiology And Drug Safety 1996, 5: 149-154. PMID: 15073831, DOI: 10.1002/(sici)1099-1557(199605)5:3<149::aid-pds222>3.0.co;2-i.Peer-Reviewed Original ResearchCalcium channel blockersIncidence of angioedemaWhite patientsHigh riskGreater incidenceGreater riskEnzyme (ACE) inhibitor-associated angioedemaRate of angioedemaRetrospective cohort studyRisk of angioedemaACEI exposureACEI useACEI usersAngioedema incidenceCCB usersCohort studyAngioedema casesFirst episodeACEIsChannel blockersAngioedemaMedicaid recipientsFull cohortEnzyme inhibitorsChronic exposure